Z BIOTECH, LLC

Biotech · Private

Sialoglycan Recognizing Probes (SGRPs) — engineered microbial-derived protein probes for detecting and characterizing sialoglycans in biological samples via standard lab methods (ELISA, flow cytometry

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Total capital: $5.4M

Federal grants: $5.4M; 12 awards · 2017–2025; Rank in peer group#11 of 42
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 2; 2 pending · first 2022; Rank in peer group#17 of 42

Capital timeline

Latest events

Aug 2025Federal grantHealth and Human S · Phase I · Development and Commercialization of Sialoglycan-Recognizing Probes$307K
Aug 2025Federal grantHealth and Human S · Phase I · Development of TACA Glycan Library and Related Glycomics Products$314K
Dec 2024Federal grantHealth and Human S · Phase I · Development of a GBP-based glycosylation analysis system$307K
Jan 2023Federal grantHealth and Human S · Phase II · Bioinformatic Tools for Interpretation of Glycan Array Data$545K
Jan 2023Federal grantHealth and Human S · Phase II · A Comprehensive 5K Plus Glycan Microarray$454K
Feb 2022Federal grantHealth and Human S · Phase II · Bioinformatic Tools for Interpretation of Glycan Array Data$545K
Jan 2022Federal grantHealth and Human S · Phase II · A Comprehensive 5K Plus Glycan Microarray$519K

Show 5 earlier federal awards

Feb 2021Federal grantHealth and Human S · Phase II · A Comprehensive 5K Plus Glycan Microarray$941K
Jan 2021Federal grantHealth and Human S · Phase II · Bioinformatic Tools for Interpretation of Glycan Array Data$557K
Dec 2018Federal grantHealth and Human S · Phase I · Bioinformatic Tools for Interpretation of Glycan Array Data$572K
Jul 2018Federal grantHealth and Human S · Phase I · A Comprehensive 5K plus Glycan Microarray$150K
Jul 2017Federal grantHealth and Human S · Phase I · A Comprehensive 5K plus Glycan Microarray$155K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 42 peers

Line = median

Biotech · Instrument

Federal grants#11 · top 26%
Granted patents#17 · top 40%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 2 granted of 4

May 23, 2023GrantedMultivalent Glycan Microarray PlatformUSPTOUS 11,656,224
Jan 25, 2022GrantedMultivalent Glycan Microarray PlatformUSPTOUS 11,231,415
PendingMultivalent Glycan Microarray PlatformUSPTOApplication 62335341

Show all 4 patent records

Multivalent Glycan Microarray PlatformMay 23, 2023 · US 11,656,224Granted
Multivalent Glycan Microarray PlatformJan 25, 2022 · US 11,231,415Granted
Multivalent Glycan Microarray PlatformApplication 62335341Pending
Multivalent Glycan Microarray PlatformApplication PCTUS2017031942Pending

InsitroSimilar federal contract value in Biotech · null in contracts
Nurix TherapeuticsSimilar federal contract value in Biotech · null in contracts
FIVE ELEVEN PHARMA, INC.Similar federal contract value in Biotech · null in contracts
Antios Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
aTYR PHARMA INCSimilar federal contract value in Biotech · null in contracts
Liberation Bioindustries, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.